Navigation Links
Thoratec Presentation at Raymond James Conference to Be Webcast
Date:3/3/2009

PLEASANTON, Calif., March 3 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it will be participating in the Raymond James 30th Annual Institutional Investors Conference on Monday, March 9.

David Smith, executive vice president and chief financial officer, will provide an update on the company, beginning at 8:05 a.m., Eastern Daylight Time, (5:05 a.m., Pacific Daylight Time).

The presentation will be available through the conference website at http://www.wsw.com/webcast/rj43/thor/ or on the company's website at http://www.thoratec.com.

Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's product lines include the Thoratec(R) VAD (Ventricular Assist Device) and HeartMate(R) LVAS (Left Ventricular Assist System) with more than 12,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) division supplies point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web sites at http://www.thoratec.com or http://www.itcmed.com.


'/>"/>
SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
2. Thoratec Reports 34 Percent Increase in 2008 Revenues
3. Thoratec Schedules Fiscal 2008 Year-End Conference Call, Webcast
4. Thoratec Presentation at Piper Jaffary Conference to be Webcast
5. Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
6. Thoratec Schedules Second Quarter 2008 Conference Call, Webcast
7. Thoratec Schedules First Quarter 2008 Conference Call, Webcast
8. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
9. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
10. Thoratecs ITC Division Receives FDA Warning Letter
11. Thoratec Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... pilot study of ActiGraph’s CentrePoint Data Hub in a sample of ... of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. ...
(Date:4/28/2017)... ... ... NuevaCare, a leading home care agency based in San Mateo, California, but ... to announce information upgrades to its blog in the form of WordPress tags. The ... as home care (generally) as well as senior care and home care agency issues. ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... ... April 27, 2017 , ... The American Brain Foundation last ... in Neurology Award (PLINA). The couple joins a prestigious list of past PLINA ... Mondale, actor Michael J. Fox and former U.S. Attorney General Janet Reno. , ...
(Date:4/27/2017)... ... April 27, 2017 , ... Offering the purest product of its ... times purer and more potent than the market has seen before. Swissx uses proprietary ... well as a patented chromatography process for extraction, to produce its CBD oil--maximizing its ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... 2017 Eyevensys, a private biotechnology ... gene expression technology that enables the safe, local, sustained ... a wide range of ophthalmic diseases, announces it has ... Regulatory Agency (MHRA) to advance its technology into clinical ... The ...
Breaking Medicine Technology: